1h Free Analyst Time
The breast Cancer monoclonal antibodies market is forecasted to grow by USD 19.2 billion during 2023-2028, accelerating at a CAGR of 13.97% during the forecast period. The report on the breast Cancer monoclonal antibodies market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of breast Cancer, rising number of patient support initiatives for breast Cancer awareness, and increasing demand for minimally invasive therapies for breast Cancer treatment.
The breast Cancer monoclonal antibodies market is segmented as below:
By End-user
- Hospitals
- Research institutes
- Others
By Type
- Humanized
- Human
- Chimeric
- Murine
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the breast Cancer monoclonal antibodies market covers the following areas:
- Breast Cancer monoclonal antibodies market sizing
- Breast Cancer monoclonal antibodies market forecast
- Breast Cancer monoclonal antibodies market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by End-user
7 Market Segmentation by Type
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global breast cancer monoclonal antibodies market: Amgen Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Celldex Therapeutics Inc, Celltrion Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., Johnson and Johnson Services Inc., MacroGenics Inc., Merck KGaA, Novartis AG, Pfizer Inc., Puma Biotechnology Inc., Sanofi SA, Seagen Inc., Teva Pharmaceutical Industries Ltd., and Viatris Inc..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is increase in number of product approvals and expanded product pipeline."
According to the report, one of the major drivers for this market is the increasing prevalence of breast cancer.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Amgen Inc.
- AstraZeneca Plc
- Boehringer Ingelheim International GmbH
- Bristol Myers Squibb Co.
- Celldex Therapeutics Inc
- Celltrion Co. Ltd.
- Daiichi Sankyo Co. Ltd.
- Eisai Co. Ltd.
- F. Hoffmann La Roche Ltd.
- Gilead Sciences Inc.
- Johnson and Johnson Services Inc.
- MacroGenics Inc.
- Merck KGaA
- Novartis AG
- Pfizer Inc.
- Puma Biotechnology Inc.
- Sanofi SA
- Seagen Inc.
- Teva Pharmaceutical Industries Ltd.
- Viatris Inc.
